Type 2 diabetes mellitus in patients with ischemic stroke – A nationwide study
Authors' conclusion
The prevalence of T2D in IS increased over time. The 30- and 365-day mortality rates decreased over the time-period but were consistently higher in IS with co-morbid T2D. Readmissions were also higher in IS with T2D. This highlights an urgent need for strategies to further improve the prognosis in IS patients with co-morbid T2D.
Study context
- Population
- All ischemic stroke (IS) events in Denmark, 2004–2020IS events
- Participants
- 169,262 events
- Exposure
- IS with co-morbid T2D vs IS without diabetes
- T2Dn = 24,479
- Outcome
- Prevalence of T2D among IS patients and time trends in risk profile, glucose-lowering medications, quality of care and clinical outcomes
Methodological detailsnationwide, adjusted for age, sex, stroke severity, co-morbidity and socio-economic factors
- Nationwide
- Adjusted for age, sex, stroke severity, co-morbidity and socio-economic factors
Main finding
As reported in the abstract
Prevalence of T2D in IS, 2004-2006
12.0%
Prevalence of T2D in IS, 2019-2020
17.0%
Observational data: associations, not effects.
Further findings
- Adjusted absolute 30-day mortality risk in IS with T2D · 2004-2006
- 9.9%
- Adjusted absolute 30-day mortality risk in IS with T2D · 2019-2020
- 7.8%
30-day mortality, adjusted risk ratios (aRR) · 2004-2006 and 2019-2020
- aRR 2004-2006
- 1.22 95% CI (1.09-1.37)
- aRR 2019-2020
- 1.29 (1.11-1.50)
365-day mortality, aRR · 2004-2006
- aRR of 365-day mortality, 2004-2006
- 1.20 (1.12-1.29)
365-day mortality, aRR · 2019-2020
- aRR of 365-day mortality, 2019-2020
- 1.34 (1.22-1.47)
30- and 365-day readmissions
- 30- and 365-day readmission rates consistently higher in IS with T2D
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →